KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 4707 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy. PMID 39477187 · J Thorac Oncol · 2025-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. PMID 39442617 · Ann Oncol · 2025-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial. PMID 39395662 · J Thorac Oncol · 2025-Feb The study is a secondary, supplementary analysis from a definitive Phase III randomized trial in lung cancer, but it lacks a drug-containing intervention. The trial is a surgical comparison (segmentectomy vs. lobectomy) without any drug therapy component. Therefore, it does not meet the criterion of having a drug-containing intervention.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05). PMID 39383487 · J Clin Oncol · 2025-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial. PMID 39374473 · J Clin Oncol · 2025-Feb Meets all inclusion criteria: oncology (NSCLC), human, randomized, Phase III trial, time-to-event endpoints (PFS, OS with HRs), drug intervention (EGFR-TKI), and is an original final result report.
H L S B
旧组与严格 v3 交集 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. PMID 39365958 · J Clin Oncol · 2025-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST-elevation myocardial infarction: A randomized controlled trial. PMID 39359014 · Br J Clin Pharmacol · 2025-Feb The record is a randomized Phase III trial with a drug intervention (colchicine) and original results, but it is not an oncology study (it is a cardiology study for STEMI), and its primary endpoints are biomarkers, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial. PMID 39261236 · Eur Urol Oncol · 2025-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost-effectiveness analysis. PMID 39246032 · Head Neck · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. PMID 39213466 · J Clin Oncol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. PMID 39089633 · J Hepatol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature. PMID 39030437 · Clin Transl Oncol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201. PMID 41397917 · Oncologist · 2025-Dec-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial. PMID 41436191 · BMJ · 2025-Dec-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 4 Panel · risk visible
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma. PMID 41429779 · Blood Cancer J · 2025-Dec-22 The report is an original results publication from a phase 2/3 trial in multiple myeloma, which is oncology, human, and involves a drug intervention. However, the abstract explicitly describes this as a 'subanalysis of the non-randomized phase 2 component,' which lacks randomization. Furthermore, the primary endpoint reported is renal response (a response rate), not a time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier/HR analysis. The deterministic review signal for time-to-event is correctly false. Therefore, it does not meet the criteria for a definitive randomized trial with a time-to-event endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial. PMID 41423619 · Nat Commun · 2025-Dec-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data. PMID 41423272 · J Immunother Cancer · 2025-Dec-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 10 Panel · risk visible
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. PMID 41037766 · J Clin Oncol · 2025-Dec-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 3 Panel · risk unclear
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. PMID 41413016 · Signal Transduct Target Ther · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. PMID 41124204 · N Engl J Med · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial. PMID 40991848 · Blood · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 3 Figure · 8 Panel · risk unclear
Recombinant human type-5 adenovirus (H101) combined with radiofrequency ablation versus traditional radiofrequency ablation for hepatocellular carcinoma ≤ 3 cm: a phase III randomized controlled trial. PMID 41403317 · Int J Surg · 2025-Dec-16 The record is a Phase III randomized trial in human oncology with a primary time-to-event efficacy endpoint (DFS) and a drug-containing intervention (H101). It reports original formal results.
H S B
严格 v3 独有 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 3 Panel · risk visible
LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. PMID 41065506 · Clin Cancer Res · 2025-Dec-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial. PMID 41020765 · Clin Cancer Res · 2025-Dec-15 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis. PMID 41463210 · Cancers (Basel) · 2025-Dec-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
[Immunotherapy for urological cancers in 2025]. PMID 41385769 · Magy Onkol · 2025-Dec-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. PMID 41124210 · N Engl J Med · 2025-Dec-11 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009. PMID 41213101 · J Clin Oncol · 2025-Dec-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. PMID 41187298 · J Clin Oncol · 2025-Dec-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. PMID 40991874 · J Clin Oncol · 2025-Dec-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 4 Panel · risk unclear
Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study). PMID 41240533 · Eur J Cancer · 2025-Dec-09 The study is an original Phase III randomized trial with a drug intervention (letrozole) and is oncology-focused in humans. However, the primary endpoint is incidence (5-year incidence of invasive BC), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) requiring Kaplan-Meier or HR for survival/disease progression. The hazard ratio provided is for incidence, not a standard time-to-event outcome.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial. PMID 41207182 · Eur J Cancer · 2025-Dec-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis. PMID 41197289 · Eur J Cancer · 2025-Dec-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial. PMID 41175805 · Eur J Cancer · 2025-Dec-09 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Can NaCl predict or even enhance responses to immunotherapy in cancer? PMID 41138602 · Eur J Cancer · 2025-Dec-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial. PMID 41138601 · Eur J Cancer · 2025-Dec-09 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma. PMID 40829107 · Blood Adv · 2025-Dec-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. PMID 41072417 · Cancer Cell · 2025-Dec-08 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. PMID 41354932 · J Hematol Oncol · 2025-Dec-07 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW. PMID 41381060 · Cancer Res Treat · 2025-Dec-05 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer. PMID 41360427 · J Immunother Cancer · 2025-Dec-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma. PMID 41345095 · Blood Cancer J · 2025-Dec-04 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 5 Figure · 10 Panel · risk unclear
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial. PMID 40939190 · Blood · 2025-Dec-04 The record describes a Phase III trial with drug interventions and time-to-event endpoints, but it lacks explicit evidence of randomization (the abstract describes comparing outcomes based on different regimens chosen by local practice, not randomized assignment). Therefore, the required criterion of randomization is not met.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. PMID 41339316 · Nat Commun · 2025-Dec-03 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 11 Panel · risk unclear
Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU). PMID 41331921 · BMC Cancer · 2025-Dec-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma. PMID 40891733 · Jpn J Clin Oncol · 2025-Dec-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs. PMID 41327119 · BMC Cancer · 2025-Dec-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial. PMID 41100113 · JAMA Oncol · 2025-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial. PMID 41037308 · JAMA Oncol · 2025-Dec-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 4 Panel · risk visible
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials. PMID 41037274 · JAMA Oncol · 2025-Dec-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed